For the quarter ending 2026-03-31, RNA made $19,635K in revenue. -$16,633K in net income. Net profit margin of -84.71%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 19,635 | 860 | 12,475 | 3,847 |
| Research and development | 16,657 | 166,596 | 154,948 | 138,125 |
| General and administrative | 20,258 | 88,742 | 46,333 | 36,864 |
| Total operating expenses | 36,915 | 255,338 | 201,281 | 174,989 |
| Loss from operations | -17,280 | -254,478 | -188,806 | -171,142 |
| Interest income | - | 17,854 | 14,744 | 14,478 |
| Other expense | - | -477 | -380 | -651 |
| Other income, net | 647 | 17,377 | 14,364 | 13,827 |
| Net loss and comprehensive loss | -16,633 | -237,101 | -174,442 | -157,315 |
| Net unrealized (gaines) losss on marketable securities | - | 807 | -4 | -1,084 |
| Foreign currency translation adjustment | - | -14 | -5 | 96 |
| Comprehensive loss | - | -236,308 | -174,451 | -158,303 |
| Basic EPS | -0.97 | -1.534 | -1.27 | -1.21 |
| Diluted EPS | -0.97 | -1.534 | -1.27 | -1.21 |
| Basic Average Shares | 17,105,643 | 154,091,000 | 137,895,000 | 129,622,000 |
| Diluted Average Shares | 17,105,643 | 154,091,000 | 137,895,000 | 129,622,000 |
Atrium Therapeutics, Inc. (RNA)
Atrium Therapeutics, Inc. (RNA)